173 related articles for article (PubMed ID: 11223564)
21. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
Winkler MH; Khan FA; Hoh IM; Okeke AA; Sugiono M; McInerney P; Boustead GB; Persad R; Kaisary AV; Gillatt DA
BJU Int; 2004 Apr; 93(6):725-9. PubMed ID: 15049980
[TBL] [Abstract][Full Text] [Related]
22. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
23. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
24. [PSA kinetics after total prostatectomy].
Riedinger JM; Eche N; Fulla Y; Thuillier F
Ann Biol Clin (Paris); 2009; 67(1):39-46. PubMed ID: 19189884
[TBL] [Abstract][Full Text] [Related]
25. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
[TBL] [Abstract][Full Text] [Related]
26. [A survey of radical surgery without neoadjuvant therapy for patients with stage B and C prostatic carcinoma].
Matsuzaki J; Kanda F; Watanabe T; Ouchi H; Tsuchiya F; Fukuda M; Satomi Y
Hinyokika Kiyo; 2001 Jan; 47(1):5-10. PubMed ID: 11235223
[TBL] [Abstract][Full Text] [Related]
27. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
28. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
Mouraviev V; Sun L; Madden JF; Mayes JM; Moul JW; Polascik TJ
Urology; 2007 Dec; 70(6):1141-5. PubMed ID: 18158035
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
31. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic strategy for prostate specific antigen (PSA) failure after radical prostatectomy].
Kinoshita H; Kamoto T; Mitsumori M; Kiyokawa T; Habuchi T; Kakehi Y; Hiraoka M; Ogawa O
Gan To Kagaku Ryoho; 2003 Jan; 30(1):32-7. PubMed ID: 12557702
[TBL] [Abstract][Full Text] [Related]
33. [A case of papillary adenocarcinoma of the prostate].
Kurokawa T; Kato N; Morikawa S; Kanai S
Hinyokika Kiyo; 2003 Jul; 49(7):415-7. PubMed ID: 12968485
[TBL] [Abstract][Full Text] [Related]
34. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Eur Urol; 2004 Nov; 46(5):571-8. PubMed ID: 15474265
[TBL] [Abstract][Full Text] [Related]
35. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
36. [Carcinosarcoma of the prostate: a case report].
Yoshida T; Ujike T; Uemura M; Nin M; Nishimura K; Miyoshi S; Kawano K
Hinyokika Kiyo; 2007 Nov; 53(11):817-9. PubMed ID: 18051809
[TBL] [Abstract][Full Text] [Related]
37. Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone.
Erbersdobler A; Huhle S; Palisaar J; Graefen M; Hammerer P; Noldus J; Huland H
Prostate Cancer Prostatic Dis; 2002; 5(4):279-84. PubMed ID: 12627212
[TBL] [Abstract][Full Text] [Related]
38. The surgical learning curve for prostate cancer control after radical prostatectomy.
Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
[TBL] [Abstract][Full Text] [Related]
39. [Endometrioid adenocarcinoma of the prostate: a case report].
Tsutahara K; Fukuhara S; Mori N; Hara T; Yamaguchi S; Adachi S; Fujisue K
Hinyokika Kiyo; 2004 Sep; 50(9):649-52. PubMed ID: 15518134
[TBL] [Abstract][Full Text] [Related]
40. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
